The overweight patient: Practical guide of intervention in primary health care;El paciente con exceso de peso: Guía práctica de actuación en Atención Primaria

Revista Espanola de Obesidad

Volumn 4, Issue 1, 2006, Pages 33-44

  Bellido, Diego ^a,b  

^a UNIVERSITY OF A CORUÑA   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ENDOCRINOLOGY; HUMAN; OBESITY; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PRIMARY HEALTH CARE; PSYCHOLOGIST; REVIEW; SPAIN; WEIGHT REDUCTION;

EID: 33646878108     PISSN: 16966112     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Aranceta Bartrina J, Serra Majem L, Foz Sala M, Moreno Esteban B. Prevalencia de obesidad en España. Med Clin (Barc) 2005; 125: 460-6.
2. Arrigabalaga JJ, Calañas Continente A, Vidal J, Masmiquel L, Díaz Fernández MJ, Garcia Luna PP, et al. Guía de práctica clínica para el manejo del sobrepeso y la obesidad en personas adultas. Endocrinol Nutr 2003; 50 (supl 4): 1-39.
3. Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Med Clin (Barc) 2000; 115: 587-97.
4. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.
5. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873-83.
6. Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. Int J Obes 2001; 25: 496-501.